Hematological toxicity of carboplatin for gynecological cancer according to body mass index-Reference-Cited by-同舟云学术

Hematological toxicity of carboplatin for gynecological cancer according to body mass index

Published:2016-06-10 Issue:9 Volume:72 Page:1083-1089
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Gutierrez Fernando,Gonzalez-de-la-Fuente Guillermo Antonio,Nazco Gloria Julia,Oramas Juana,Batista Norberto

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-016-2080-7.pdf

Reference39 articles.

1. Ozols RF, Bundy BN, Greer BE, et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 21:3194–3200

2. Neijt JP, Engelholm SA, Tuxen MK, et al. (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18:3084–3092

3. Yuichi Ando, Tomoya Shimokata, Yoshinari Yasuda, Yoshinari Hasegawa (2014). Carboplatin dosing for adult Japanese patients. Nagoya J Med Sci 76. 1~9

4. van der Vijgh WJF (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21(4):242–261

5. Kloft C, Siegert W, Beyer J, Jaehde U (2002) Toxicity of high-dose carboplatin: ultrafiltered and no total plasma pharmacokinetics is of clinical relevance. J Clin Pharmacol 42(7):762–773

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic study of carboplatin using various overweight-correcting dosing algorithms and biomarkers in patients with varying BMI categories;2024-08-17

2. The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer;Cancer Treatment and Research Communications;2023

3. Pelvic bones ADC could help to predict severe hematologic toxicity in patients undergoing concurrent chemoradiotherapy for cervical cancer;Magnetic Resonance Imaging;2022-12

4. Predictors of Acute Hematologic Toxicity in Women Receiving Extended-Field Chemoradiation for Cervical Cancer: Do Known Pelvic Radiation Bone Marrow Constraints Apply?;Advances in Radiation Oncology;2022-11

5. Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma;Acta Oncologica;2021-10-11